ArticleDermatology and therapyPublished
Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- Dermatology and therapy
- Published
- Topic
- Clinical care
- Subject terms
- Safety; Psoriasis; Oral; Deucravacitinib; Icotrokinra
- PubMed ID
- 42663861
- PubMed Central ID
- PMC13650227
- Open access
- Yes, open
- Added to directory
- Source checked